© 1999 American Heart Association, Inc.
Rapid Communication |
Cyclosporine Attenuates Pressure-Overload Hypertrophy in Mice While Enhancing Susceptibility to Decompensation and Heart Failure
From the Cardiovascular and Pulmonary Research Institute (T.M., C.H., K.A., G.T., S.F.V.), Allegheny University of the Health Sciences, Pittsburgh, Pa; University of Texas Southwestern Medical Center at Dallas (T.A.M., E.N.O.), Department of Molecular Biology and Oncology, Dallas, Tex.
Correspondence to Stephen F. Vatner, MD, Cardiovascular and Pulmonary Research Institute, Allegheny University of the Health Sciences, South Tower, 320 East North Ave, Pittsburgh, PA 15212-4772.
Abstract—Left ventricular hypertrophy (LVH) is a compensatory mechanism to cope with pressure overload. Recently, a calcineurin pathway mediating LVH and its prevention by cyclosporine was reported. We examined whether calcineurin mediates LVH due to pressure overload in mice. Pressure overload was induced by aortic banding in 53 mice (32 treated with cyclosporine [25 mg · kg-1 · d-1], 21 treated with vehicle). There were 17 sham-operated mice (9 treated with vehicle, 8 treated with cyclosporine). At 3 weeks after surgery, LV weight to body weight was greater in the nontreatment banded group (4.39±0.16 mg/g) than in the cyclosporine-treated banded group (3.95±0.14 mg/g, P<0.05), with both groups being greater compared with the entire group of sham-operated mice (3.02±0.04 mg/g). The pressure gradient between the ascending and abdominal aorta was not different between the cyclosporine-treated (49.6±6.1 mm Hg) and nontreatment groups (48.7±4.6 mm Hg). Although LV systolic pressure was lower in the cyclosporine-treated banded animals, LV systolic wall stress was similar in the nontreatment banded group and in the cyclosporine-treated group. However, LV dP/dt was lower (P=0.05) in the cyclosporine-treated banded group (4774±656 mm Hg/s) than in the nontreatment banded group (6604±516 mm Hg/s). During the protocol, 23 of 32 mice in the cyclosporine-treated group and 9 of 21 mice in the nontreatment group died. All deaths occurred within 10 days after surgery. Deaths caused by heart failure were 7.2-fold higher (P<0.05) in the cyclosporine-treated group, whereas deaths due to other causes were not different between the 2 groups. In addition, LV function of mice was assessed at 48 hours after banding; LV ejection fraction measured with echocardiography was lower (P<0.05) in the cyclosporine-treated banded group (66±3.0%) than in the nontreatment banded group (79±1.5%), whereas LV systolic wall stresses were similar. Calcineurin phosphatase activity was depressed similarly in both cyclosporine-treated groups compared with both nontreatment groups. Thus, cyclosporine could attenuate, but not prevent, LVH at the expense of inhibiting an important compensatory mechanism in response to pressure overload, resulting in reduced LV wall stress and function and increased susceptibility to decompensation and heart failure.
Key Words: calcineurin • Ca2+ • left ventricular hypertrophy • aortic banding
This article has been cited by other articles:
 |
|
 |
|
  R. J. Gelpi, S. Gao, P. Zhai, L. Yan, C. Hong, L. M. A. Danridge, H. Ge, Y. Maejima, M. Donato, M. Yokota, et al. Genetic inhibition of calcineurin induces diastolic dysfunction in mice with chronic pressure overload Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1814 - H1819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Schaeffer, J. DeSantiago, J. Yang, T. P. Flagg, A. Kovacs, C. J. Weinheimer, M. Courtois, T. C. Leone, C. G. Nichols, D. M. Bers, et al. Impaired contractile function and calcium handling in hearts of cardiac-specific calcineurin b1-deficient mice Am J Physiol Heart Circ Physiol, October 1, 2009; 297(4): H1263 - H1273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. F. Oliveira, J. C. B. Ferreira, E. R. M. Gomes, N. A. Paixão, N. P. L. Rolim, A. Medeiros, S. Guatimosim, and P. C. Brum Cardiac anti-remodelling effect of aerobic training is associated with a reduction in the calcineurin/NFAT signalling pathway in heart failure mice J. Physiol., August 1, 2009; 587(15): 3899 - 3910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Loyer, A. M. Gomez, P. Milliez, M. Fernandez-Velasco, P. Vangheluwe, L. Vinet, D. Charue, E. Vaudin, W. Zhang, Y. Sainte-Marie, et al. Cardiomyocyte Overexpression of Neuronal Nitric Oxide Synthase Delays Transition Toward Heart Failure in Response to Pressure Overload by Preserving Calcium Cycling Circulation, June 24, 2008; 117(25): 3187 - 3198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Zhai, S. Gao, E. Holle, X. Yu, A. Yatani, T. Wagner, and J. Sadoshima Glycogen Synthase Kinase-3{alpha} Reduces Cardiac Growth and Pressure Overload-induced Cardiac Hypertrophy by Inhibition of Extracellular Signal-regulated Kinases J. Biol. Chem., November 9, 2007; 282(45): 33181 - 33191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mirotsou, V. J. Dzau, R. E. Pratt, and E. O. Weinberg Physiological genomics of cardiac disease: quantitative relationships between gene expression and left ventricular hypertrophy Physiol Genomics, January 12, 2007; 27(1): 86 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. C. Okere, M. E. Young, T. A. McElfresh, D. J. Chess, V. G. Sharov, H. N. Sabbah, B. D. Hoit, P. Ernsberger, M. P. Chandler, and W. C. Stanley Low Carbohydrate/High-Fat Diet Attenuates Cardiac Hypertrophy, Remodeling, and Altered Gene Expression in Hypertension Hypertension, December 1, 2006; 48(6): 1116 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Dickhout and R. C. Austin Proteasomal Regulation of Cardiac Hypertrophy: Is Demolition Necessary for Building? Circulation, October 24, 2006; 114(17): 1796 - 1798. [Full Text] [PDF]
|
|
|
|
|
|
C. Depre, Q. Wang, L. Yan, N. Hedhli, P. Peter, L. Chen, C. Hong, L. Hittinger, B. Ghaleh, J. Sadoshima, et al. Activation of the Cardiac Proteasome During Pressure Overload Promotes Ventricular Hypertrophy Circulation, October 24, 2006; 114(17): 1821 - 1828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Katada, T. Meguro, H. Saito, A. Ohashi, T. Anzai, S. Ogawa, and T. Yoshikawa Persistent Cardiac Aldosterone Synthesis in Angiotensin II Type 1A Receptor-Knockout Mice After Myocardial Infarction Circulation, May 3, 2005; 111(17): 2157 - 2164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Pillai, H. M. Russell, J. Raman, V. Jeevanandam, and M. P. Gupta Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H486 - H496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Schreiner, K. Kelemen, J. Zehelein, R. Becker, J. C. Senges, A. Bauer, F. Voss, P. Kraft, H. A. Katus, and W. Schoels Biventricular hypertrophy in dogs with chronic AV block: effects of cyclosporin A on morphology and electrophysiology Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2891 - H2898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Selvetella, E. Hirsch, A. Notte, G. Tarone, and G. Lembo Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence Cardiovasc Res, August 15, 2004; 63(3): 373 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D Molkentin Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs Cardiovasc Res, August 15, 2004; 63(3): 467 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Diedrichs, M. Chi, B. Boelck, U. Mehlhorm, and R. H.G. Schwinger Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure Eur J Heart Fail, January 1, 2004; 6(1): 3 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liao, S. Takashima, Y. Asano, M. Asakura, A. Ogai, Y. Shintani, T. Minamino, H. Asanuma, S. Sanada, J. Kim, et al. Activation of Adenosine A1 Receptor Attenuates Cardiac Hypertrophy and Prevents Heart Failure in Murine Left Ventricular Pressure-Overload Model Circ. Res., October 17, 2003; 93(8): 759 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Li, A. Yatani, S.-J. Kim, G. Takagi, K. Irie, Q. Zhang, V. Karoor, C. Hong, G. Yang, J. Sadoshima, et al. Neurally-mediated increase in calcineurin activity regulates cardiac contractile function in absence of hypertrophy Cardiovasc Res, September 1, 2003; 59(3): 649 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Okumura, G. Takagi, J.-i. Kawabe, G. Yang, M.-C. Lee, C. Hong, J. Liu, D. E. Vatner, J. Sadoshima, S. F. Vatner, et al. Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload PNAS, August 19, 2003; 100(17): 9986 - 9990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Morisco, J. Sadoshima, B. Trimarco, R. Arora, D. E. Vatner, and S. F. Vatner Is treating cardiac hypertrophy salutary or detrimental: the two faces of Janus Am J Physiol Heart Circ Physiol, April 1, 2003; 284 (4): H1043 - H1047. [Full Text] [PDF]
|
|
|
|
|
|
L. M. Semeniuk, D. L. Severson, A. J. Kryski, S. L. Swirp, J. D. Molkentin, and H. J. Duff Time-dependent systolic and diastolic function in mice overexpressing calcineurin Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H425 - H430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Dong, Y. Duan, J. Guo, D. E Roach, S. L Swirp, L. Wang, J.P Lees-Miller, R.S Sheldon, J. D Molkentin, and H. J Duff Overexpression of calcineurin in mouse causes sudden cardiac death associated with decreased density of K+ channels Cardiovasc Res, February 1, 2003; 57(2): 320 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-j. Youn, H. Piao, J.-s. Kwon, S.-y. Choi, H.-s. Kim, D.-g. Park, D.-w. Kim, Y.-g. Kim, and M.-c. Cho Effects of the calcineurin dependent signaling pathway inhibition by cyclosporin A on early and late cardiac remodeling following myocardial infarction Eur J Heart Fail, December 1, 2002; 4(6): 713 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Wilkins, L. J. De Windt, O. F. Bueno, J. C. Braz, B. J. Glascock, T. F. Kimball, and J. D. Molkentin Targeted Disruption of NFATc3, but Not NFATc4, Reveals an Intrinsic Defect in Calcineurin-Mediated Cardiac Hypertrophic Growth Mol. Cell. Biol., November 1, 2002; 22(21): 7603 - 7613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J Wilkins and J. D Molkentin Calcineurin and cardiac hypertrophy: Where have we been? Where are we going? J. Physiol., May 15, 2002; 541(1): 1 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Ritter, S. Hack, K. Schuh, N. Rothlein, A. Perrot, K. J. Osterziel, H. D. Schulte, and L. Neyses Calcineurin in Human Heart Hypertrophy Circulation, May 14, 2002; 105(19): 2265 - 2269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. N Petrashevskaya, I. Bodi, M. Rubio, J. D Molkentin, and A. Schwartz Cardiac function and electrical remodeling of the calcineurin-overexpressed transgenic mouse Cardiovasc Res, April 1, 2002; 54(1): 117 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Kassiri, C. Zobel, T.-T. T. Nguyen, J. D. Molkentin, and P. H. Backx Reduction of Ito Causes Hypertrophy in Neonatal Rat Ventricular Myocytes Circ. Res., March 22, 2002; 90(5): 578 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. F Bueno, E. van Rooij, J. D Molkentin, P. A Doevendans, and L. J De Windt Calcineurin and hypertrophic heart disease: novel insights and remaining questions Cardiovasc Res, March 1, 2002; 53(4): 806 - 821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Zhang Old and new tools to dissect calcineurin's role in pressure-overload cardiac hypertrophy Cardiovasc Res, February 1, 2002; 53(2): 294 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zou, Y. Hiroi, H. Uozumi, E. Takimoto, H. Toko, W. Zhu, S. Kudoh, M. Mizukami, M. Shimoyama, F. Shibasaki, et al. Calcineurin Plays a Critical Role in the Development of Pressure Overload-Induced Cardiac Hypertrophy Circulation, July 3, 2001; 104(1): 97 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mardini, A. S. Mihailidou, A. Wong, and H. H. Rasmussen Cyclosporine and FK506 Differentially Regulate the Sarcolemmal Na+-K+ Pump J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 804 - 810. [Abstract] [Full Text]
|
|
|
|
|
|
L. A. Leinwand Calcineurin inhibition and cardiac hypertrophy: A matter of balance PNAS, March 13, 2001; 98(6): 2947 - 2949. [Full Text] [PDF]
|
|
|
|
|
|
L. J. De Windt, H. W. Lim, O. F. Bueno, Q. Liang, U. Delling, J. C. Braz, B. J. Glascock, T. F. Kimball, F. del Monte, R. J. Hajjar, et al. Targeted inhibition of calcineurin attenuates cardiac hypertrophy invivo PNAS, March 13, 2001; 98(6): 3322 - 3327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Rothermel, T. A. McKinsey, R. B. Vega, R. L. Nicol, P. Mammen, J. Yang, C. L. Antos, J. M. Shelton, R. Bassel-Duby, E. N. Olson, et al. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo PNAS, March 13, 2001; 98(6): 3328 - 3333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kato, M. Sano, S. Miyoshi, T. Sato, D. Hakuno, H. Ishida, H. Kinoshita-Nakazawa, K. Fukuda, and S. Ogawa Calmodulin Kinases II and IV and Calcineurin Are Involved in Leukemia Inhibitory Factor-Induced Cardiac Hypertrophy in Rats Circ. Res., November 10, 2000; 87(10): 937 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Sakata, T. Masuyama, K. Yamamoto, N. Nishikawa, H. Yamamoto, H. Kondo, K. Ono, K. Otsu, T. Kuzuya, T. Miwa, et al. Calcineurin Inhibitor Attenuates Left Ventricular Hypertrophy, Leading to Prevention of Heart Failure in Hypertensive Rats Circulation, October 31, 2000; 102(18): 2269 - 2275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Molkentin Calcineurin and Beyond : Cardiac Hypertrophic Signaling Circ. Res., October 27, 2000; 87(9): 731 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shimoyama, D. Hayashi, Y. Zou, E. Takimoto, M. Mizukami, K. Monzen, S. Kudoh, Y. Hiroi, Y. Yazaki, R. Nagai, et al. Calcineurin Inhibitor Attenuates the Development and Induces the Regression of Cardiac Hypertrophy in Rats With Salt-Sensitive Hypertension Circulation, October 17, 2000; 102(16): 1996 - 2004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Rusnak and P. Mertz Calcineurin: Form and Function Physiol Rev, October 1, 2000; 80(4): 1483 - 1521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M.L Janssen, O. Zeitz, B. Keweloh, U. Siegel, L. S Maier, P. Barckhausen, B. Pieske, J. Prestle, S. E Lehnart, and G. Hasenfuss Influence of cyclosporine A on contractile function, calcium handling, and energetics in isolated human and rabbit myocardium Cardiovasc Res, July 1, 2000; 47(1): 99 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Hill, M. Karimi, W. Kutschke, R. L. Davisson, K. Zimmerman, Z. Wang, R. E. Kerber, and R. M. Weiss Cardiac Hypertrophy Is Not a Required Compensatory Response to Short-Term Pressure Overload Circulation, June 20, 2000; 101(24): 2863 - 2869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Oie, R. Bjornerheim, O. P. F. Clausen, and H. Attramadal Cyclosporin A inhibits cardiac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats Am J Physiol Heart Circ Physiol, June 1, 2000; 278(6): H2115 - H2123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. W. Lim, L. J. De Windt, L. Steinberg, T. Taigen, S. A. Witt, T. R. Kimball, and J. D. Molkentin Calcineurin Expression, Activation, and Function in Cardiac Pressure-Overload Hypertrophy Circulation, May 23, 2000; 101(20): 2431 - 2437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Eto, K. Yonekura, M. Sonoda, N. Arai, M. Sata, S. Sugiura, K. Takenaka, A. Gualberto, M. L. Hixon, M. W. Wagner, et al. Calcineurin Is Activated in Rat Hearts With Physiological Left Ventricular Hypertrophy Induced by Voluntary Exercise Training Circulation, May 9, 2000; 101(18): 2134 - 2137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. De Windt, H. W. Lim, S. Haq, T. Force, and J. D. Molkentin Calcineurin Promotes Protein Kinase C and c-Jun NH2-terminal Kinase Activation in the Heart. CROSS-TALK BETWEEN CARDIAC HYPERTROPHIC SIGNALING PATHWAYS J. Biol. Chem., April 28, 2000; 275(18): 13571 - 13579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Carson and L. Wei Integrin signaling's potential for mediating gene expression in hypertrophying skeletal muscle J Appl Physiol, January 1, 2000; 88(1): 337 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Herzig and J. Neumann Effects of Serine/Threonine Protein Phosphatases on Ion Channels in Excitable Membranes Physiol Rev, January 1, 2000; 80(1): 173 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. He and M. C. LaPointe Interleukin-1{beta} Regulates the Human Brain Natriuretic Peptide Promoter via Ca2+-Dependent Protein Kinase Pathways Hypertension, January 1, 2000; 35(1): 292 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Mervaala, D. N. Muller, J.-K. Park, R. Dechend, F. Schmidt, A. Fiebeler, M. Bieringer, V. Breu, D. Ganten, H. Haller, et al. Cyclosporin A Protects Against Angiotensin II-Induced End-Organ Damage in Double Transgenic Rats Harboring Human Renin and Angiotensinogen Genes Hypertension, January 1, 2000; 35(1): 360 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shimoyama, D. Hayashi, E. Takimoto, Y. Zou, T. Oka, H. Uozumi, S. Kudoh, F. Shibasaki, Y. Yazaki, R. Nagai, et al. Calcineurin Plays a Critical Role in Pressure Overload-Induced Cardiac Hypertrophy Circulation, December 14, 1999; 100(24): 2449 - 2454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. N. Olson and J. D. Molkentin Prevention of Cardiac Hypertrophy by Calcineurin Inhibition : Hope or Hype? Circ. Res., April 2, 1999; 84(6): 623 - 632. [Full Text] [PDF]
|
|
|
|
|
|
R. A. Walsh Calcineurin Inhibition as Therapy for Cardiac Hypertrophy and Heart Failure : Requiescat in Pace? Circ. Res., April 2, 1999; 84(6): 741 - 743. [Full Text] [PDF]
|
|
|
|
|
|
A. Murat, C. Pellieux, H.-R. Brunner, and T. Pedrazzini Calcineurin Blockade Prevents Cardiac Mitogen-activated Protein Kinase Activation and Hypertrophy in Renovascular Hypertension J. Biol. Chem., December 22, 2000; 275(52): 40867 - 40873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Young, F. A. Laws, G. W. Goodwin, and H. Taegtmeyer Reactivation of Peroxisome Proliferator-activated Receptor alpha Is Associated with Contractile Dysfunction in Hypertrophied Rat Heart J. Biol. Chem., November 21, 2001; 276(48): 44390 - 44395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Crabtree Calcium, Calcineurin, and the Control of Transcription J. Biol. Chem., January 19, 2001; 276(4): 2313 - 2316. [Full Text] [PDF]
|
|
|
|
|
|
Y. Liao, F. Ishikura, S. Beppu, M. Asakura, S. Takashima, H. Asanuma, S. Sanada, J. Kim, H. Ogita, T. Kuzuya, et al. Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validation Am J Physiol Heart Circ Physiol, May 1, 2002; 282(5): H1703 - H1708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kakita, K. Hasegawa, E. Iwai-Kanai, S. Adachi, T. Morimoto, H. Wada, T. Kawamura, T. Yanazume, and S. Sasayama Calcineurin Pathway Is Required for Endothelin-1-Mediated Protection Against Oxidant Stress-Induced Apoptosis in Cardiac Myocytes Circ. Res., June 22, 2001; 88(12): 1239 - 1246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Kassiri, C. Zobel, T.-T. T. Nguyen, J. D. Molkentin, and P. H. Backx Reduction of Ito Causes Hypertrophy in Neonatal Rat Ventricular Myocytes Circ. Res., March 22, 2002; 90(5): 578 - 585. [Abstract] [Full Text] [PDF]
|
|